Hunter R. Murdock sold $1.4M of AXSM
General Counsel at Axsome Therapeutics, Inc.. 13,514 shares at an average of $101.42, traded Jun 20, 2025, filed Jun 23, 2025.
Score components
- +15RoleOfficer
- +25Trade size$1.4M at market
- +20Share of holdings soldSold 100% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-089158, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 20, 2025 | MOption exercise Common Stock10b5-1 | +7,500 | $29.91 | $224k | 7,500 | Jun 23, 2025 |
| Jun 20, 2025 | SOpen-market sale Common Stock10b5-1 | -7,500 | $102.47 | $769k | 0 | Jun 23, 2025 |
| Jun 23, 2025 | MOption exercise Common Stock10b5-1 | +6,014 | $29.91 | $180k | 6,014 | Jun 23, 2025 |
| Jun 23, 2025 | SOpen-market sale Common Stock10b5-1 | -6,014 | $100.12 | $602k | 0 | Jun 23, 2025 |
| Jun 20, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -7,500 | $0.00 | $0 | 22,383 | Jun 23, 2025 |
| Jun 23, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,014 | $0.00 | $0 | 16,369 | Jun 23, 2025 |
Related signals
Other insiders at Axsome Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | Axsome Therapeutics, Inc. | Mark L. Jacobson Chief Operating Officer | $2.1M 10,000 shares | -100% | |
| 33Weak | Axsome Therapeutics, Inc. | Hunter R. Murdock General Counsel | $2.3M 22,500 shares | -300% | |
| 45Moderate | Axsome Therapeutics, Inc. | Mark L. Jacobson Chief Operating Officer | $2.8M 25,000 shares | -81% | |
| 30Weak | Axsome Therapeutics, Inc. | Mark Coleman director | $783k 7,500 shares | -14% | |
| 38Weak | Axsome Therapeutics, Inc. | Mark L. Jacobson Chief Operating Officer | $4.2M 40,673 shares | -154% | |
| 37Weak | Axsome Therapeutics, Inc. | Mark Coleman director | $322k 3,000 shares | -5% | |
| 22Weak | Axsome Therapeutics, Inc. | Nick Pizzie Chief Financial Officer | $2.0M 15,000 shares | -28% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.